Shanghai InnoStar Bio-tech Co., Ltd. was established in 2010. As a leading contract research organization, we adhere to the core values of ‘Science orientated, Quality first, Integrity & dedication, Win-win cooperation’, and strive for excellence through our services with high quality, win customers by recognized reputation, add values by technical innovation, and maintain efficiency by streamlined management. InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification form the National Medical Products Administration (NMPA), OECD GLP certification from the Netherlands GLP monitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. The company has the industry-leading international service capabilities to provide global pharmaceutical companies and research institutions with a full range of one-stop new drug research and development services, including early-stage druggability assessment, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, and biomarkers and translational research.InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).
InnoStar provides employees opportunities to best use their talents and a dual career
development channel combining “management channel” and “professional channel” based on to their abilities.
Copyright © 2017-2021©Shanghai InnoStar Bio-tech Co., Ltd. All Rights Reserved. Created By VPABrand.com